256 related articles for article (PubMed ID: 37464424)
1. DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming.
Yang X; Wang X; Yang Y; Li Z; Chen Y; Shang S; Wang Y
J Transl Med; 2023 Jul; 21(1):481. PubMed ID: 37464424
[TBL] [Abstract][Full Text] [Related]
2. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
[TBL] [Abstract][Full Text] [Related]
3. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Signal; 2023 May; 105():110626. PubMed ID: 36758683
[TBL] [Abstract][Full Text] [Related]
4. Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study.
Shi X; Yang Y; Shang S; Wu S; Zhang W; Peng L; Huang T; Zhang R; Ren R; Mi J; Wang Y
BMC Cancer; 2019 Nov; 19(1):1072. PubMed ID: 31703632
[TBL] [Abstract][Full Text] [Related]
5. DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction between EZH2 and DNMT3A.
Yang Y; Dai Y; Yang X; Wu S; Wang Y
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067359
[No Abstract] [Full Text] [Related]
6. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
[TBL] [Abstract][Full Text] [Related]
7. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations.
Lu J; Guo Y; Yin J; Chen J; Wang Y; Wang GG; Song J
Nat Commun; 2024 Apr; 15(1):3111. PubMed ID: 38600075
[TBL] [Abstract][Full Text] [Related]
9. Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement.
Dai YJ; Wang YY; Huang JY; Xia L; Shi XD; Xu J; Lu J; Su XB; Yang Y; Zhang WN; Wang PP; Wu SF; Huang T; Mi JQ; Han ZG; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2017 May; 114(20):5237-5242. PubMed ID: 28461508
[No Abstract] [Full Text] [Related]
10. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
[TBL] [Abstract][Full Text] [Related]
11. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
12. A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3A
Lu R; Wang J; Ren Z; Yin J; Wang Y; Cai L; Wang GG
Cancer Res; 2019 Jul; 79(14):3583-3594. PubMed ID: 31164355
[TBL] [Abstract][Full Text] [Related]
13. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.
Scheller M; Ludwig AK; Göllner S; Rohde C; Krämer S; Stäble S; Janssen M; Müller JA; He L; Bäumer N; Arnold C; Gerß J; Schönung M; Thiede C; Niederwieser C; Niederwieser D; Serve H; Berdel WE; Thiem U; Hemmerling I; Leuschner F; Plass C; Schlesner M; Zaugg J; Milsom MD; Trumpp A; Pabst C; Lipka DB; Müller-Tidow C
Nat Cancer; 2021 May; 2(5):527-544. PubMed ID: 35122024
[TBL] [Abstract][Full Text] [Related]
14. Rapid and accurate remethylation of DNA in
Li Y; Abel HJ; Cai M; LaValle TA; Yin T; Helton NM; Smith AM; Miller CA; Ley TJ
Sci Adv; 2024 Feb; 10(5):eadk8598. PubMed ID: 38295174
[TBL] [Abstract][Full Text] [Related]
15. RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with
Sidorova OA; Sayed S; Paszkowski-Rogacz M; Seifert M; Camgöz A; Roeder I; Bornhäuser M; Thiede C; Buchholz F
Cells; 2022 Mar; 11(5):. PubMed ID: 35269477
[No Abstract] [Full Text] [Related]
16. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
[TBL] [Abstract][Full Text] [Related]
17. Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs.
Yang L; Liu Y; Zhang N; Ding X; Zhang W; Shen K; Huang L; Zhou J; Cui S; Zhu Z; Hu Z; Xiao M
Oncotarget; 2017 May; 8(18):30395-30409. PubMed ID: 28418922
[TBL] [Abstract][Full Text] [Related]
18. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.
Tang L; Huang H; Tang Y; Li Q; Wang J; Li D; Zhong Z; Zou P; You Y; Cao Y; Kong Y; Guo A; Zhou S; Li H; Meng F; Xiao Y; Zhu X
Clin Transl Med; 2022 Sep; 12(9):e1043. PubMed ID: 36163632
[TBL] [Abstract][Full Text] [Related]
19. Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation.
Que Y; Li H; Lin L; Zhu X; Xiao M; Wang Y; Zhu L; Li D
Front Immunol; 2021; 12():653030. PubMed ID: 34093541
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
